Европейски съюз -
български -
EMA (European Medicines Agency)
rapilysin
actavis group ptc ehf - ретеплаза - Инфаркт на миокарда - Антитромботични агенти - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.
Европейски съюз -
български -
EMA (European Medicines Agency)
beyfortus
astrazeneca ab - nirsevimab - Имунни серуми и имуноглобулини - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.
Европейски съюз -
български -
EMA (European Medicines Agency)
byooviz
samsung bioepis nl b.v. - ранимизумаб - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - Офталмологични - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
Европейски съюз -
български -
EMA (European Medicines Agency)
ximluci
stada arzneimittel ag - ранимизумаб - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Офталмологични - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
България -
български -
Изпълнителна агенция по лекарствата
ibuprofen b. braun 600 mg/100 ml solution for infusion
600 mg/100 ml solution for infusion
България -
български -
Изпълнителна агенция по лекарствата
ibuprofen b. braun 400 mg/100 ml solution for infusion
400 mg/100 ml solution for infusion
България -
български -
Изпълнителна агенция по лекарствата
ondansetron b. braun 0,08 mg/ml solution for infusion
0,08 mg/ml solution for infusion
България -
български -
Изпълнителна агенция по лекарствата
rocuronium b. braun 10 mg/ml solution for injection/infusion
10 mg/ml solution for injection/infusion
Европейски съюз -
български -
EMA (European Medicines Agency)
iblias
bayer ag - octocog Алфа - Хемофилия А - Антихеморагични - Лечение и профилактика на кървене при пациенти с хемофилия А (дефицит на вроден дефицит на фактор vІІІ). iblias може да се използва за всички възрастови групи.
Европейски съюз -
български -
EMA (European Medicines Agency)
abrysvo
pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - Инфекции на респираторния синцитиален вирус - Ваксини - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. Вижте раздели 4. 2 и 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.